Jump to main content
Jump to site search

Issue 43, 2012
Previous Article Next Article

Designing organometallic compounds for catalysis and therapy

Author affiliations


Bioorganometallic chemistry is a rapidly developing area of research. In recent years organometallic compounds have provided a rich platform for the design of effective catalysts, e.g. for olefin metathesis and transfer hydrogenation. Electronic and steric effects are used to control both the thermodynamics and kinetics of ligand substitution and redox reactions of metal ions, especially RuII. Can similar features be incorporated into the design of targeted organometallic drugs? Such complexes offer potential for novel mechanisms of drug action through incorporation of outer-sphere recognition of targets and controlled activation features based on ligand substitution as well as metal- and ligand-based redox processes. We focus here on η6-arene, η5-cyclopentadienyl sandwich and half-sandwich complexes of FeII, RuII, OsII and IrIII with promising activity towards cancer, malaria, and other conditions.

Graphical abstract: Designing organometallic compounds for catalysis and therapy

Back to tab navigation

Publication details

The article was received on 31 Jan 2012, accepted on 20 Mar 2012 and first published on 19 Apr 2012

Article type: Feature Article
DOI: 10.1039/C2CC30678F
Citation: Chem. Commun., 2012,48, 5219-5246
  •   Request permissions

    Designing organometallic compounds for catalysis and therapy

    A. L. Noffke, A. Habtemariam, A. M. Pizarro and P. J. Sadler, Chem. Commun., 2012, 48, 5219
    DOI: 10.1039/C2CC30678F

Search articles by author